Dmg Group, LLC Gilead Sciences, Inc. Transaction History

Dmg Group, LLC

$121 Million
Q3 2024

A detailed history of Dmg Group, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Dmg Group, LLC holds 14,155 shares of GILD stock, worth $1.29 Million. This represents 0.98% of its overall portfolio holdings.

Number of Shares

14,155

Previous 13,348 6.05%

Holding current value

$1.29 Million

Previous $915,000 29.62%

% of portfolio

0.98%

Previous 0.79%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	BUY	$66.59 - $83.99 $53,738 - $67,779	807 Added 6.05%	14,155 $1.19 Million
Q2 2024 Jul 16, 2024	SELL	$63.15 - $72.88 $79,947 - $92,266	-1,266 Reduced 8.66%	13,348 $915,000
Q1 2024 Apr 19, 2024	SELL	$71.58 - $87.29 $5,225 - $6,372	-73 Reduced 0.5%	14,614 $1.07 Million
Q4 2023 Jan 10, 2024	SELL	$73.27 - $83.09 $2,710 - $3,074	-37 Reduced 0.25%	14,687 $1.19 Million
Q3 2023 Oct 26, 2023	BUY	$73.94 - $80.67 $49,761 - $54,290	673 Added 4.79%	14,724 $1.1 Million
Q2 2023 Jul 13, 2023	BUY	$76.01 - $86.7 $75,401 - $86,006	992 Added 7.6%	14,051 $1.08 Million
Q1 2023 Apr 24, 2023	BUY	$77.31 - $88.08 $209,664 - $238,872	2,712 Added 26.21%	13,059 $1.09 Million
Q4 2022 Feb 06, 2023	BUY	$62.32 - $89.47 $129,812 - $186,366	2,083 Added 25.21%	10,347 $884,000
Q3 2022 Oct 27, 2022	BUY	$59.54 - $68.01 $101,337 - $115,753	1,702 Added 25.94%	8,264 $515,000
Q2 2022 Aug 09, 2022	BUY	$57.72 - $65.01 $90,620 - $102,065	1,570 Added 31.45%	6,562 $407,000
Q1 2022 Apr 25, 2022	SELL	$57.92 - $72.58 $105,472 - $132,168	-1,821 Reduced 26.73%	4,992 $311,000
Q4 2021 Jan 31, 2022	BUY	$64.88 - $73.64 $442,027 - $501,709	6,813 New	6,813 $458,000

Others Institutions Holding GILD

# of Institutions

1,926

Shares Held

992M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $114B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dmg Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dmg Group, LLC with notifications on news.

Account